IP Library Granted Patent US 10,919,835
Granted Patent B2
US 10,919,835 · App. 16/799,176 · Granted Feb 16, 2021

Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids

Inventors: Roshantha A. Chandraratna (San Juan Capistrano, CA); Vidyasagar Pradeep Vuligonda (Irvine, CA); Thomas Jacks (South Plainfield, NJ); Peter Wade (South Plainfield, NJ); Andrew Thompson (South Plainfield, NJ)
Assignee: Io Therapeutics, Inc.
C07C57/50A61K31/192A61K31/198C07C29/44C07C33/36C07C33/38C07C51/255C07B2200/07C07C2601/02C07C2602/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,919,835
App. No.
16/799,176
Granted
Feb 16, 2021
Kind
B2
Abstract

Provided herein are compounds useful for the preparation of compounds that have retinoid-like biological activity. Also provided herein are processes for the preparation of compounds that have retinoid-like biological activity.

Claims (32)

1. A method of making Compound 38,

or a pharmaceutically acceptable salt thereof,

comprising a synthetic process of preparing intermediate compound 8, (Z)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)but-2-en-1-ol, of Formula (XII),

or a solvate thereof,

by reacting compound 4, sodium (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)boronate of Formula (XVI),

or a solvate thereof,

with compound 7, (Z)-3-iodobut-2-en-1-ol, of Formula (XVII),

or a solvate thereof,

in the presence of Pd/C and a base, such that the compound of Formula (XII) or a solvate thereof is prepared.

2. The method of claim 1 , wherein Compound 38 has an enantiomeric excess of Compound A,

of at east about 98.0%.

3. The method of claim 1 , wherein the base is K 2 CO 3 .

4. The method of claim 1 , wherein the reaction comprises a solvent comprising EtOH.

5. A method of synthesizing compound 8, (Z)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)but-2-en-1-ol, of Formula (XII),

or a solvate thereof,

by reacting compound 4, sodium (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)boronate of Formula (XVI),

or a solvate thereof,

with compound 7, (Z)-3-iodobut-2-en-1-ol, of Formula (XVII),

or a solvate thereof,

in the presence of Pd/C and a base, such that the compound of Formula (XII) or a solvate thereof is prepared.

6. The method of claim 5 , wherein the base is K 2 CO 3 .

7. The method of claim 5 , wherein the reaction comprises a solvent comprising EtOH.

8. The method of claim 1 , wherein the synthetic process of preparing intermediate compound 8 is carried out at kilogram scale.

9. The method of claim 1 , wherein the synthetic process of preparing intermediate compound 8 is carried out utilizing at least 1 kilogram of each of compound 4 and compound 7.

10. The method of claim 1 , wherein the synthetic process of preparing intermediate compound 8 produces at least 1 kilogram of compound 8.

11. The method of claim 1 , wherein the synthetic process of preparing intermediate compound 8 has a yield of about 84%.

12. The method of claim 1 , wherein the synthetic process of preparing intermediate compound 8 has a yield of at least 84%.

13. The method of claim 5 , wherein synthesizing compound 8 is carried out at kilogram scale.

14. The method of claim 5 , wherein synthesizing compound 8 is carried out utilizing at least 1 kilogram of each of compound 4 and compound 7.

15. The method of claim 5 , wherein synthesizing compound 8 produces at least 1 kilogram of compound 8.

16. The method of claim 5 , wherein synthesizing compound 8 has a yield of about 84%.

17. The method of claim 5 , wherein synthesizing compound 8 has a yield of at least 84%.

Assignments (5)
CONFIRMATORY LICENSE Recorded Oct 12, 2022
From: IO THERAPEUTICS, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061656/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2020
From: VULIGONDA, VIDYASAGAR PRADEEP
To: IO THERAPEUTICS, INC.
Reel/Frame 051906/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2020
From: CHANDRARATNA, ROSHANTHA A.
To: IO THERAPEUTICS, INC.
Reel/Frame 051906/0216 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2020
From: JACKS, THOMAS; WADE, PETER; THOMPSON, ANDREW
To: J-STAR RESEARCH, INC.
Reel/Frame 051906/0303 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2020
From: J-STAR RESEARCH, INC.
To: IO THERAPEUTICS, INC.
Reel/Frame 051906/0362 →
Continuity (4)
Continuation 16194141 · Nov 16, 2018
Provisional Application 62671137 · May 14, 2018
Provisional Application 62588163 · Nov 17, 2017
Related Publication 20200190008A1 · Jun 18, 2020